with their burden often extending to longer-term complications such as event recurrence and post-thrombotic syndrome (PTS). Few data exist on the overall economic burden of DVT and PE and their ...

It's actually kind of paradoxical in the way that I sort of look at it. On one hand, a patient who presents at a young age is ...

In this retrospective analysis of a large-claims database that is representative of the U.S. commercially insured population, we investigated the annualized total reimbursed health care costs for ...

Key findings from 2024 focused on conditions like vaccine-induced immune thrombotic thrombocytopenia, immune thrombocytopenia ...

The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.

D. Boral Capital initiated coverage of Omeros (OMER) with a Buy rating and $36 price target With Narsoplimab now poised for U.S. approval, followed by Europe, Omeros is “at an inflection point,” ...

Vinod Kambli has been hospitalised in a critical state but is now stable Kambli said to the PTI “It is because the doctor ...

Fintel reports that on December 23, 2024, D. Boral Capital initiated coverage of Omeros (NasdaqGM:OMER) with a Buy ...

US biotech Regeneron Pharmaceuticals has announced positive Phase II results for two novel monoclonal antibodies targeting ...

Apellis has had its highs and lows this year. Read what makes APLS a stock to watch for potential short-term gains before and after approval.

Bioxodes enrolls patients in phase 2a clinical trial of BIOX-101 in intracerebral hemorrhagic stroke: Gosselies, Belgium Saturday, December 21, 2024, 15:00 Hrs [IST] Bioxodes SA, ...